Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Notes Payables (2021 - 2023)

ImmunityBio (IBRX) has disclosed Notes Payables for 5 consecutive years, with $481.9 million as the latest value for Q2 2023.

  • Quarterly Notes Payables rose 60.59% to $481.9 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $481.9 million through Jun 2023, up 60.59% year-over-year, with the annual reading at $431.9 million for FY2022, 44.33% up from the prior year.
  • Notes Payables for Q2 2023 was $481.9 million at ImmunityBio, up from $441.6 million in the prior quarter.
  • The five-year high for Notes Payables was $481.9 million in Q2 2023, with the low at $299.2 million in Q4 2021.
  • Average Notes Payables over 3 years is $375.7 million, with a median of $366.0 million recorded in 2022.
  • The sharpest move saw Notes Payables skyrocketed 44.33% in 2022, then soared 60.59% in 2023.
  • Over 3 years, Notes Payables stood at $299.2 million in 2021, then surged by 44.33% to $431.9 million in 2022, then grew by 11.58% to $481.9 million in 2023.
  • According to Business Quant data, Notes Payables over the past three periods came in at $481.9 million, $441.6 million, and $431.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.